Chicago, Illinois 60611

  • Obesity


The overall objective of this study is to evaluate the first rigorously optimized, remotely delivered treatment for obesity against the current gold standard treatment in a head-to-head randomized controlled trial. The investigators will be comparing the previously developed and optimized behavioral weight loss intervention (APP) to the Diabetes Prevention Program (DPP), to evaluate program weight-loss success and cost-effectiveness.

Study summary:

The proposed study seeks to determine if the APP program is an effective, resource-sensitive strategy to manage weight for obesity, as compared to the DPP program. During the 24-week active intervention phase, participants will be randomized to one of two treatments: 1) APP, wherein participants receive calorie, fat, and physical activity goals via a Smartphone application for self-monitoring, online educational readings, and biweekly sessions with a Health Promotionist; or 2) DPP, wherein participants are guided to self-monitor their physical activity, food intake, and weight via a participant log, and are guided through 16 sessions by a Health Promotionist. Assessments to track progress will occur remotely at the 3-month, 6-month, and 12-month time points of the program.


Inclusion Criteria: - BMI 30-45 - Weight stable - Own a Smartphone and be willing to install our Smartphone app - Willing to conduct video conference calls with study staff Exclusion Criteria: - Enrolled in any formal weight loss program - Taking anti-obesity medications - Not taking medications that may cause weight gain - Unstable medical conditions - Diabetes requiring insulin supplementation - Crohn's Disease - Diagnosis of obstructive sleep apnea requiring intervention (i.e., CPAP) - Assistive devices for mobility - Hospitalizations for a psychiatric disorder within the past 5 years - Cardiovascular disease symptoms while performing moderate intensity exercise - Pregnancy, trying to get pregnant, or lactating. - Bulimia or binge eating disorder - Reports of active suicidal ideation - Current substance abuse or dependence besides nicotine dependence



Primary Contact:

Principal Investigator
Angela Pfammatter, PhD
Northwestern University

Laura Scanlan, MS
Phone: 312-503-1395

Backup Contact:


Location Contact:

Chicago, Illinois 60611
United States

Laura Scanlan, MS
Phone: 312-503-1395

Site Status: Recruiting

Data Source:

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.